Literature DB >> 6170297

Inhibition by azelastine of the immunologically induced histamine release from isolated guinea pig mast cells.

B Fischer, W Schmutzler.   

Abstract

4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazinone (azelastine, A 5610) did not affect the spontaneous histamine release but inhibited effectively the allergic histamine release from isolated mesenteric mast cells of actively sensitized guinea pigs. At 10(-6) mol/l concentration the inhibition was almost equal to that caused by adrenaline (10(-8) mol/l).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6170297

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Azelastine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content.

Authors:  M M Little; D R Wood; T B Casale
Journal:  Agents Actions       Date:  1989-08

Review 3.  Histamine2 (H2)-receptor antagonists in the treatment of urticaria.

Authors:  T C Theoharides
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

4.  Azelastine and allergen transduction signal in MC9 mast cells.

Authors:  K Fanous; R P Garay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

5.  Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs.

Authors:  N Chand; J Pillar; W Diamantis; R D Sofia
Journal:  Agents Actions       Date:  1985-07

6.  Lipid Cubic Systems for Sustained and Controlled Delivery of Antihistamine Drugs.

Authors:  Michele Dully; Miriama Ceresnakova; David Murray; Tewfik Soulimane; Sarah P Hudson
Journal:  Mol Pharm       Date:  2021-09-21       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.